Related Experiment Video
Updated: Jul 3, 2025
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
miR-6883 downregulates HIF1α in colorectal and breast cancer cells
Nicole A Jensen-Velez1,2, Lindsey Carlsen3,4,5,6,1, Wafik S El-Deiry1,4,5,6,7,3
1Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Pathology and Laboratory Medicine, The Warren Alpert Medical School, Brown University, Providence, RI 02903, USA.
Abstract:
Colorectal cancer (CRC) and breast cancer (BC) are deadly diseases that rank as the second and fourth leading causes of cancer-related deaths, respectively. We have previously shown that miR-6883 targets CDK4/6 and that palbociclib-mediated CDK4/6 inhibition destabilizes HIF1α. We hypothesize that miR-6883 downregulates HIF1α in CRC and BC cells. miR-6883 was transfected into cells under normoxia or hypoxia and western blot analysis revealed that miR-6883 downregulates CDK4/6 and HIF1α in CRC and BC cells, pointing to miR-6883 as a promising therapeutic to target hypoxic tumors or HIF1α-deregulated cancer cells. Future studies will further investigate miR-6883 as a cancer biomarker, effects on HIF-related proteins, and therapeutic uses in vivo .
Insights
MicroRNA-6883 (miR-6883) downregulates hypoxia-inducible factor 1-alpha (HIF1α) in colorectal and breast cancer cells. This finding suggests miR-6883 as a potential therapeutic for targeting hypoxic or HIF1α-deregulated cancers.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Colorectal cancer (CRC) and breast cancer (BC) are leading causes of cancer mortality.
- CDK4/6 inhibitors like palbociclib destabilize HIF1α.
- miR-6883 has been identified as a target of CDK4/6.
Purpose of the Study:
- To investigate the hypothesis that miR-6883 downregulates HIF1α in CRC and BC cells.
- To explore the potential of miR-6883 as a therapeutic agent against hypoxic tumors.
Main Methods:
- Transfection of miR-6883 into CRC and BC cell lines under normoxia and hypoxia.
- Western blot analysis to assess protein levels of CDK4/6 and HIF1α.
Main Results:
- miR-6883 transfection led to the downregulation of CDK4/6 in both CRC and BC cells.
- miR-6883 also significantly downregulated HIF1α expression under both normoxic and hypoxic conditions.
- These results confirm the inhibitory effect of miR-6883 on CDK4/6 and HIF1α.
Conclusions:
- miR-6883 effectively downregulates both CDK4/6 and HIF1α in colorectal and breast cancer cells.
- miR-6883 represents a promising therapeutic candidate for cancers characterized by hypoxia or HIF1α dysregulation.
- Further research is warranted to evaluate miR-6883 as a biomarker and for in vivo therapeutic applications.
Related Concept Videos
01:22MicroRNAs
01:15Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...